Right now, the drugs come with a hefty price tag. Ozempic typically runs 8,800 to 11,000 rupees ($95–$119) per month, while ...

The Food and Drug Administration approved a higher-dose version of a popular class of obesity drugs on Thursday, the latest ...

Broad generic availability of semaglutide is not expected until the early 2030s, which means most Americans will stay on branded Ozempic and Wegovy for years to come. Some patients may eye Canadian ...

Eli Lilly's next-generation obesity drug retatrutide helped significantly reduce A1C levels for people with diabetes while helping them lose weight.

Novo Nordisk said the U.S. Food and Drug Administration approved a higher dosage of its Wegovy weight-loss medication, a boost for the Danish drugmaker as it faces growing competition in the obesity ...

U.S. regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy. The Food and Drug Administration approved a 7.2-milligram dose of Novo Nordisk's ...

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

Novo Nordisk A/S won approval to sell a high-dose version of its blockbuster Wegovy obesity shot in the US, allowing it to offer weight loss closer to that of rival Eli Lilly & Co.’s competing shot ...

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

Eli Lilly’s investigational first-in-class GIP, glucagon-like peptide 1 receptor (GLP-1R) and glucagon triple hormone ...

It's 'definitely not a measure of fatness,' and it doesn't accurately define what it means to be overweight. Body mass index ...

Key Takeaways Nearly 16% of U.S. high schoolers are now obese, a significant jump from a decade agoFewer teens are attempting to lose weight today compared to 2013Significant racial disparities exist, ...